Jasmine Cui, InnoCare CEO
InnoCare bags Chinese rights to Incyte CAR-T rival Monjuvi in bid to expand in-house pipeline
Merck veteran Jasmine Cui has turned Beijing-based InnoCare into a $4 billion company largely on the strength of a single BTK inhibitor and a clutch of earlier stage assets.
But on Tuesday, the biotech expanded its pipeline, striking a deal with Incyte for the Delaware biotech’s newly US-approved CD-19 antibody Monjuvi. Under the agreement, InnoCare will pay Incyte $35 million and promise $82.5 million in milestones for rights to market the cancer drug in China and its surrounding regions.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
